Eyecare company Bausch + Lomb (NYSE: BLCO) met Wall Street’s revenue expectations in Q3 2026, with sales up 7.3% year on year to $1.38 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $5.5 billion at the midpoint. Its non-GAAP profit of $0.34 per share was 54.7% above analysts’ consensus estimates.
Is now the time to buy BLCO? Find out in our full research report (it’s free for active Edge members).
Bausch + Lomb (BLCO) Q3 2026 highlights:
- Revenue $1.38 billion vs S&P analysts’ estimates of $1.37 billion (7.3% year-on-year growth, in line)
- Adjusted EPS $0.34 vs S&P analysts’ estimates of $0.22 (54.7% beat)
- Adjusted EBITDA $325 million vs analyst estimates of $270.9 million (23.6% margin, 20% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.5 billion at the midpoint from $5.49 billion
- EBITDA guidance $1.12 billion at the midpoint for the full year, above analyst estimates of $1.05 billion
- Operating margin 11.3%, up from 7.4% in the same quarter last year
- Constant currency revenue rose 8% year on year (6% in the same quarter last year)
StockStory’s take
Bausch + Lomb’s third quarter results were met with a notably positive market response, reflecting investor enthusiasm for the company’s ability to expand margins while delivering steady revenue growth across all business segments. Management attributed the performance to disciplined execution and a broad-based contribution from pharmaceuticals, surgical products, and vision care. Interim CEO Tom Appio emphasized the importance of ongoing portfolio strength and operational improvements, stating, “We are building momentum across the business and the trajectory is encouraging.” The quarter was further defined by strong cash generation and continued progress in margin expansion initiatives.
Looking forward, Bausch + Lomb’s updated guidance is shaped by sustained momentum in its core franchises and a renewed focus on operational efficiency. Management highlighted ongoing investment in its R&D pipeline, particularly in next-generation contact lenses and dry eye treatments, as key drivers of future growth. CFO Osama A. Eldessouky pointed to efforts in cost optimization and manufacturing productivity, noting, “Our lower fixed cost structure has driven improvement and positions us to continue expanding operating leverage.” The company remains committed to balancing growth, margin expansion, and cash generation as it progresses toward its multi-year strategic targets.
Key insights from management’s remarks
Management cited robust performance in pharmaceuticals, contact lenses, and premium surgical products as central to the quarter’s margin gains and strong cash flow. R&D investments and cost discipline also played significant roles.
- Pharmaceuticals momentum: The dry eye portfolio, led by Miebo and Xiidra, saw strong growth, with Miebo revenue up 42%. Management emphasized these brands as foundational for continued expansion in a large and growing market.
- Contact lens strength: The contact lens segment, especially daily silicone hydrogel (SiHy) lenses, delivered 25% growth, with leadership highlighting broad-based momentum and a pipeline of product innovation such as Project Halo, a bioactive lens material in development.
- Premium surgical product adoption: Premium intraocular lenses (IOLs) experienced 75% growth, signaling a successful shift toward higher-margin offerings in the surgical segment. The company noted that expanding adoption and new launches, like Envista Envy in Europe, are expected to further drive profitability.
- Consumer product durability: Longstanding brands such as Lumify, now eight years post-launch, continued to post double-digit revenue growth, illustrating the durability and brand strength in the consumer portfolio.
- Operational leverage and cost control: Disciplined management of SG&A and manufacturing productivity contributed to margin expansion, with CFO Eldessouky citing network optimization and vertical integration as ongoing sources of improvement.
Drivers of future performance
Management’s outlook centers on sustaining broad-based growth while driving additional margin gains through product innovation, portfolio mix, and disciplined cost management.
- Pipeline progress and innovation: Continued advancement in R&D, particularly in next-generation contact lenses and new dry eye therapies, is expected to drive top-line growth and differentiate the company in key categories. The pending launch of the next generation of Lumify and ongoing clinical progress in projects like Project Halo are central to future performance.
- Margin expansion focus: The company aims to maintain margin momentum by optimizing product mix toward higher-margin brands (such as premium IOLs and advanced contact lenses) and further reducing SG&A expenses. Management believes these efforts will support EBITDA margin improvement in the coming years.
- Capital allocation and leverage reduction: Reducing net leverage remains a priority, with management targeting a 3.5x leverage ratio. CFO Eldessouky stated that balancing debt reduction with strategic reinvestment will guide capital allocation decisions, supporting both financial flexibility and long-term growth.
Catalysts in upcoming quarters
In the quarters ahead, we will monitor (1) the pace of adoption for premium IOLs and next-generation contact lenses, (2) progress on key clinical milestones for pipeline products such as Project Halo and dry AMD therapies, and (3) continued execution on SG&A efficiency and manufacturing productivity initiatives. Developments in capital allocation and leverage reduction will also be important signals of management’s ability to balance growth with financial discipline.
Bausch + Lomb currently trades at $20.38, up from $17.62 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Stocks that trumped tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
